This publication has been discontinued on July 19, 2011.
Strategic Analysis of Downstream Processing in Biopharmaceutical Production
Research Overview
Increased Demand for New Solutions Drives Biopharmaceuticals Market
Accounting for over forty percent of biopharmaceutical manufacturing costs,
downstream processing has been a long-standing market barrier. Low investment
due to a lack of interest by participants has resulted in a technology
bottleneck through a deficiency of specialized, high-throughput apparatus and
automation systems. Despite this setback, the biopharmaceuticals market is
expected to grow rapidly due to the lowering efficacy of existing drugs that is
increasing the demand for treatment of new diseases. To effectively exploit this
growing demand, industry focus is shifting towards technical specialization and
investments in automated systems. Innovative downstream processing technologies
are currently being developed to process new biopharmaceuticals.
Frost & Sullivanfs recent strategic analysis on downstream processing
in biopharmaceuticals production offers a comprehensive overview of downstream
processing technology dynamics and the market for contract manufacturing
organisations (CMOs).
CMOs Vital to Defeat High Cost of In-house Downstream Processing
As in-house downstream processing technologies are an expensive investment,
participants are outsourcing to CMOs. This is resulting in their gaining
prominence in the constantly evolving biopharmaceuticals market.
"Considered a key component of the biopharmaceuticals value chain, CMOs are
being used by biopharmaceuticals companies to source key intermediates and
active ingredients," says the analyst of this research. "The idea
behind this strategic move is to speed the development of new patented products
and decrease time-to-market while also providing the maximum cost efficiency and
highest possible level of innovation."
CMOs, mostly distributed across the United States, United Kingdom and
Germany, are currently investing heavily to develop their own facilities and
market leaders are offering integrated downstream processing solutions for
in-house use by major biopharmaceuticals companies.
Shift in R&D Focus Advantageous to the Global CMO Market
- A shift in R&D focus from upstream processing and drug discovery to
downstream processing ? which had earlier suffered from a lack of investment
and innovation ? is likely to benefit the world CMO market immensely.
"As the cost of installing or developing in-house downstream systems
and staying abreast of technology developments is an expensive proposition,
R&D and drug discovery firms are now outsourcing different stages of
manufacturing to CMOs. Those CMOs which invest in downstream processing
facilities are likely to benefit from this trend," says the analyst.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new
theories tested in hundreds of companies across many industries, Frost &
Sullivan has evolved its Growth Partnership Services (GPS) program that provides
established and emerging firms with powerful growth visions. Moving beyond token
mission statements, GPS provides an actionable vision to growth consulting
partners by illustrating how key intelligence and strategic research based on
defined goals can guide day-to-day behavior and overall company direction. The
foundation of Frost & Sullivan's GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related
businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common
mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximize the potential for growth within a firmfs internal and external
environment, Frost & Sullivan consultants can facilitate the creation of
strategic programs that deliver improved market success. Frost &
Sullivanfs strengths lie in combining strategic understanding with market
expertise and applying these with absolute commitment to its clientsf growth.
1 STRATEGIC ANALYSIS OF DOWNSTREAM PROCESSING IN BIOPHARMACEUTICAL PRODUCTION
- Overview
- Research Scope & Methodology
- Research Scope & Methodology
- Introduction & Background
- Introduction & Background
- Market Dynamics
- Market Dynamics
- Industry Challenges
- Key Market Trends
- Key Technology Trends
- Key Market Drivers
- Key Market Restraints
- Future Technology Dynamics
- Future Technology Dynamics
- Key Technology Drivers
- Key Technology Restraints
- Biopharmaceutical Production Costs
- Analysis of Emerging Technologies
- Integrated Solutions
- Major Challenges and Remedial Strategies
- Contract Manufacturing Organisations (CMOs)
- Contract Manufacturing Organisations (CMOs)
- Forecast Assumptions
- CMOs in Downstream Processing
- CMO Market Drivers
- CMO Market Restraints
- Key Market Engineering Measurements
- Total Market Revenue Forecast
- Revenue Analysis
- Competitive Profiles
- CMO Geographic Distribution
- Strategic Analysis & Recommendations
- Strategic Analysis & Recommendations
- Strategic Analysis
- Strategic Anticipation
- Market Maturation Process
- Competitive Framework
- Potential Threats
- Meeting the Challenge
- Meeting the Challenge - Product Pricing Strategy
- Meeting the Challenge - Strategic Postures
- Frost & Sullivan Awards
- Frost & Sullivan Awards
- Frost & Sullivan Awards Description
- Product Innovation Award
- Technology Leadership Award
- Customer Service Innovation Award
- Market Leadership Award
- Product Differentiation Innovation Award
- Decision Support Databases
- Decision Support Databases
- Global Pharmaceutical R&D Expenditure (1999-2006)
- Number of Biotechnology Companies (1999 - 2006)
- Top 10 Global Pharmaceutical Drug Sales (2003)
- Percentage of Pharmaceutical R&D Expenditure (1999-2006)
- Frost & Sullivan
- Healthcare Team
- Our Capabilities
